- Home
- SGC vs GOSS Comparison
SGC vs GOSS Comparison
Compare SGC & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGC
- GOSS
- Stock Information
- Founded
- SGC 1920
- GOSS 2015
- Country
- SGC United States
- GOSS United States
- Employees
- SGC N/A
- GOSS N/A
- Industry
- SGC Apparel
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- SGC Consumer Discretionary
- GOSS Health Care
- Exchange
- SGC Nasdaq
- GOSS Nasdaq
- Market Cap
- SGC 252.6M
- GOSS 214.7M
- IPO Year
- SGC N/A
- GOSS 2019
- Fundamental
- Price
- SGC $15.19
- GOSS $0.94
- Analyst Decision
- SGC Strong Buy
- GOSS Strong Buy
- Analyst Count
- SGC 2
- GOSS 5
- Target Price
- SGC $22.00
- GOSS $9.20
- AVG Volume (30 Days)
- SGC 74.4K
- GOSS 943.4K
- Earning Date
- SGC 11-04-2024
- GOSS 11-07-2024
- Dividend Yield
- SGC 3.69%
- GOSS N/A
- EPS Growth
- SGC N/A
- GOSS N/A
- EPS
- SGC 0.68
- GOSS N/A
- Revenue
- SGC $553,945,000.00
- GOSS $95,842,000.00
- Revenue This Year
- SGC $4.89
- GOSS N/A
- Revenue Next Year
- SGC $4.84
- GOSS N/A
- P/E Ratio
- SGC $22.40
- GOSS N/A
- Revenue Growth
- SGC 1.22
- GOSS N/A
- 52 Week Low
- SGC $7.59
- GOSS $0.45
- 52 Week High
- SGC $21.80
- GOSS $1.60
- Technical
- Relative Strength Index (RSI)
- SGC 52.90
- GOSS 45.42
- Support Level
- SGC $14.79
- GOSS $0.93
- Resistance Level
- SGC $15.28
- GOSS $1.09
- Average True Range (ATR)
- SGC 0.30
- GOSS 0.06
- MACD
- SGC 0.01
- GOSS -0.01
- Stochastic Oscillator
- SGC 50.57
- GOSS 7.37
About SGC Superior Group of Companies Inc.
Superior Group Of Companies Inc designs apparel products. The company's operating segment includes Branded Products; Healthcare Apparel and Contact Centers. It generates maximum revenue from the Branded Products segment. The Branded Products segment produce and sell customized merchandising solutions, promotional products and branded uniform programs to customers.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.